Saquinavir therapy in patients with the advanced HIV infection and liver cirrhosis

Japanese Journal of Infectious Diseases

Volumn 52, Issue 4, 1999, Pages 177-178

  Tachikawa, Natsuo ^a   Yoshizawa, Sadako ^a   Kikuchi, Yoshimi ^a   Yasuoka, Akira ^a   Oka, Shinichi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ADULT; ARTICLE; ASCITES; CASE REPORT; CLINICAL TRIAL; DRUG BLOOD LEVEL; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION;

ADULT; DRUG THERAPY, COMBINATION; HEMOPHILIA A; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; RITONAVIR; SAQUINAVIR; STAVUDINE;

EID: 0032741963     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Darby, S. C., Ewart, D. W., Giangrande, P. F. L., Spooner, R. J. D., Rizza, C. R., Dusheiko, G. M., Lee, C. A., Ludlam, C. A., Preston, F. E. and UK Haemophilia Centre Directors' Organisation (1997): Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet, 350, 1425-1431.
2. Thomas, D., Vlahov, D., Solomon, L., et al. (1995): Correlates of hepatitis C virus infections among drug users. Medicine (Baltimore), 74, 212-220.
3. Rodriguez-Rosado, R., Garcia-Samaniego, J. and Soriano, V. (1998): Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS, 12, 1256.
4. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D. and HIV Outpatient Study Investigators (1998): Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med., 338, 853-860.
5. Hse, A., Granneman, R., Cao, G., et al. (1998): Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther., 63, 453-464.
6. Cameron, D. W., Japour, A. J., Xu, Y, Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S., Angel, J. B., McMahon, D., Ho, D., Devanarayan, V., Rode, R., Salgo, M. P., Kempf, D. J., Granneman, R., Leonard, J. M. and Sun, E. (1999): Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS, 13, 213-224.
7. Barry, M. G., Concepta, M., Lloyd, J., et al. (1998): Variability in trough plasma saquinavir concentrations in HIV patients-a case for therapeutic drug monitoring. Br. J. Clin. Pharmacol., 45, 501-502.
8. Zyberberg, H., Pialoux, G., Carnot, F, Landau, A., Brechot, C. and Pol, S. (1998): Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin. Infect. Dis., 27, 1255-1258.